Explore Teva in Ireland

A doctor in Ireland is writing a prescription for a Teva medicine, to improve their patient’s outcome.

A pharmacist in Ireland is reaching for a Teva product, secure in the knowledge that Teva medicines meet the highest standards for quality and safety.

A parent in Ireland is trusting a Teva medicine to help an unwell child feel better.

We’re focused on improving how long-term conditions are managed, addressing cost-efficient prescribing and ensuring high quality joined-up care for the patient.

We're also looking at healthcare options that are fit for the future, like new technologies, innovative devices, and a fresh approach to services.

At Teva we believe that everyone should have access to quality medicine that helps manage disease, fights infection, or simply improves overall health. From in-house innovation to strategic partnerships, we are persistently discovering, developing and delivering both generic and innovative medicines.

We are not defined by any one label.

Instead, our legacy in high-quality generics enables us to leverage our capabilities to bring forward complex generics and biosimilars at scale to create more value for patients and healthcare systems, and an improved health impact.

We maximise pivotal solutions that lead to better health for our patients, in Ireland and around the world, and a stronger company for our people by delivering in the short-term to drive long-term stability.

Teva is a major employer in Ireland with hundreds of highly skilled colleagues working in our research and manufacturing facilities.

Teva employs around 650 people across two sites in the Republic of Ireland and we have one site in Northern Ireland focused on research.

Our commercial activities span the sales and support services for Teva’s large portfolio of medicines, both generics and branded innovative medicines, along with over-the-counter consumer health products.

We supply medicines to treat a wide range of diseases and conditions – from multiple sclerosis, migraine and asthma, to pain relief, cholesterol reducers and antibiotics.

Our dosage forms include extended and immediate release tablets and capsules, injectables, creams, ointments, solutions and inhalers.

This is Paul, a District Key Account Executive in the Retail Sales Team.

"I’ve worked in the Irish pharmaceutical industry for 35 years and it’s great being a small part of the medical care system that is providing hope and relief to patients on our medicines."

In 2013, Ireland introduced compulsory generic medicines substitution into the country, this led to a big change in medicine usage in Ireland – away from branded medicines to more affordable, but equally effective generic medicines. Five years later, the real economic benefit of that initiative became evident.

In 2013 the proportion of generic medicines dispensed was low, at just 11% but that figure rose to 58% in 2018, following the introduction of this legislation.02

The average price per pack of medicines has fallen from €18 in 2013, down to €6 in 2018 - that's a decrease of €12 per pack of medicine. 02

The benefits to the healthcare system and the Exchequer, and ultimately for patients are remarkable: An estimated €1.6 billion in medicine savings were counted between 2013 and 2018, solely from substituting branded medicines for an interchangeable, equally effective, generic medicines. 02

Using less expensive, high-quality generic medicines frees up valuable funds and enables them to be redirected to where patients urgently need them.

As one of Ireland’s largest suppliers of generic medicines, Teva is contributing significantly to the savings made by switching to better value, unbranded medicines.

In fact, one in eight prescription packs supplied to Irish pharmacies is a Teva pack. 03

Ireland is an important manufacturing hub for Teva’s respiratory medicines supplying healthcare services and patients all around the world.

Our teams there are experts in manufacturing both the medicine and the device, including multidose dry-powder inhalers, metered dose inhalers and e-connected inhalers for asthma and COPD.

The Waterford site quality standards are recognised as the gold standard within Teva. The site is FDA approved (which means we are approved to export our products to the US, by United States' Food and Drug Administration), along with the European Medicines Agency and multiple local regulators.

All of our manufacturing processes are validated and products are tested and certified, using state-of-the-art testing equipment throughout the manufacturing process - that ensures adherence to the highest quality and compliance standards.

At our Waterford site we make ‘smart’ digi-halers which connect with your smartphone to record data which can be analysed to inform patients and physicians about the device usage.

Using smart inhaler technology patients may be empowered to manage their condition more effectively, and healthcare professionals could get greater insight into the patient's experience and condition to make more informed treatment decisions.

This is Andy, the General Manager at Teva’s Respiratory Site in Waterford, Ireland.

"My wish is to grow into an even bigger site, producing a broader and more complex range of respiratory products and helping patients all over the world to breathe more easily."

Sudocrem^® Antiseptic Healing Cream is an absolute staple in Irish households, loved by Irish families for its ability to soothe cuts, grazes, bed sores, sunburn, eczema as well as nappy rash. We're really proud that Sudocrem^® is the top selling nappy rash product in 15 countries.

Developed in 1931 to treat nappy rash by Dublin pharmacist Thomas Smith, the classic formula has remained unchanged since then.

In 2023, Teva’s economic activities in Ireland contributed to the world GDP with €502m (including GDP contribution from R&D activities).

Teva Ireland directly contributed €173m (+8% based on 2022) to the Irish GDP and supported the Irish economy with additional €100m based on indirect and induced economic effects. Teva Ireland also supported foreign economies with €229m.04